Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Palbociclib (Iclos) vs Ibrance in Healthy Subjects
NCT06331715Phase 4Completed
- Sponsor
- Megalabs
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of palbociclib in breast cancer, sponsored by Megalabs. Started Feb 2024; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06331715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331715.